Published in Ocular Surface

TrueTear – A True Paradigm Shift In The Treatment For Dry Eye

This is editorially independent content
2 min read
TrueTear is a new treatment for dry eye which utilizes neurostimulation and was FDA approved on April 25, 2017. Here is what you need to know.
TrueTear – A True Paradigm Shift In The Treatment For Dry Eye

Dry eye is a chronic and progressive disease that negatively impacts our patients' quality of life and limits the visual treatments we prescribe.

Doctors and patients are often frustrated with the involved and complex treatment of this disease.
Dry eye is a multifactorial disease that has no cure, and the average patient requires multiple treatments. Many patients require numerous therapies such as lid hygiene, heat masks, thermal pulsation, topical anti-inflammatories, amniotic membranes, punctal occlusion and many other FDA and non-FDA approved treatments to decrease patient symptoms.

For years, doctors and patients have desired new treatment options for dry eye.

Optometry and ophthalmology are disciplines that have embraced new technology better than any other medical specialty and finally, the time for new remedies have come.
Allergan received FDA approval of its novel neurostimulation device for the treatment of dry eye on April 25, 2017.
Here’s a 36 page guide on understanding dry eye and meibomian gland dysfunction. Learn how you can treat MGD using LipiFlow, and how to bring this technology to your practice.

TrueTear was invented by a team of experts at Stanford led by Dr. Michael Ackermann, a PhD in neurostimulation.

The device was further developed in Silicone Valley, home to the world's most innovative and disruptive technologies.
This singular technology creates an entirely new treatment class in eye care representing a true paradigm shift in the treatment of dry eye.
TrueTear is a non-invasive, nasal neurostimulation device that helps the body work like it should, naturally. This is done by comfortable stimulation of the Trigeminal Nerve (CN V), which activates the entire lacrimal functional unit.
This produces true tears, containing meibum from the meibomian glands, aqueous from the lacrimal glands and mucin from goblet cell degranulation.
For decades, patients and doctors have struggled with dry eye, and both have always desired new and more efficacious treatment options.
This device offers you and your patients a new, innovative treatment option.
Josh Johnston, OD, FAAO
About Josh Johnston, OD, FAAO

Dr. Josh Johnston is the Clinical Director at Georgia Eye Partners and an adjunct faculty member at Southern College of Optometry serving as the Residency Director at GEP. He founded Oculus Consulting Partners to help eye doctors and practices start and improve their dry eye practices offering consulting that blends technology and expertise to offer simpler, more efficient, and smarter consulting.

Josh Johnston, OD, FAAO
💙 Our Sponsor
Johnson & Johnson Vision Logo